JP2025533334A5 - - Google Patents
Info
- Publication number
- JP2025533334A5 JP2025533334A5 JP2025518537A JP2025518537A JP2025533334A5 JP 2025533334 A5 JP2025533334 A5 JP 2025533334A5 JP 2025518537 A JP2025518537 A JP 2025518537A JP 2025518537 A JP2025518537 A JP 2025518537A JP 2025533334 A5 JP2025533334 A5 JP 2025533334A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- patient
- sotrasib
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263411789P | 2022-09-30 | 2022-09-30 | |
| US63/411,789 | 2022-09-30 | ||
| PCT/US2022/053130 WO2024072437A1 (en) | 2022-09-30 | 2022-12-16 | Sotorasib dosing regimen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025533334A JP2025533334A (ja) | 2025-10-06 |
| JP2025533334A5 true JP2025533334A5 (enExample) | 2026-01-28 |
Family
ID=85158814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025518537A Pending JP2025533334A (ja) | 2022-09-30 | 2022-12-16 | ソトラシブ投与レジメン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20260083741A1 (enExample) |
| EP (1) | EP4593837A1 (enExample) |
| JP (1) | JP2025533334A (enExample) |
| KR (1) | KR20250079183A (enExample) |
| AU (1) | AU2022479909A1 (enExample) |
| JO (1) | JOP20250064A1 (enExample) |
| MX (1) | MX2025003741A (enExample) |
| TW (1) | TW202415380A (enExample) |
| WO (1) | WO2024072437A1 (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013557A (es) * | 2021-05-18 | 2023-11-29 | Amgen Inc | Pauta posologica de sotorasib. |
-
2022
- 2022-12-16 WO PCT/US2022/053130 patent/WO2024072437A1/en not_active Ceased
- 2022-12-16 US US19/112,616 patent/US20260083741A1/en active Pending
- 2022-12-16 EP EP22851420.4A patent/EP4593837A1/en active Pending
- 2022-12-16 JP JP2025518537A patent/JP2025533334A/ja active Pending
- 2022-12-16 TW TW111148499A patent/TW202415380A/zh unknown
- 2022-12-16 KR KR1020257013939A patent/KR20250079183A/ko active Pending
- 2022-12-16 AU AU2022479909A patent/AU2022479909A1/en active Pending
-
2025
- 2025-03-25 JO JOJO/P/2025/0064A patent/JOP20250064A1/ar unknown
- 2025-03-28 MX MX2025003741A patent/MX2025003741A/es unknown
- 2025-09-12 US US19/327,206 patent/US20260166040A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024526145A5 (enExample) | ||
| JP2022022264A5 (enExample) | ||
| JP2023513015A5 (enExample) | ||
| JP2022533578A5 (enExample) | ||
| JP2022519375A5 (enExample) | ||
| JP2021513536A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2018505193A5 (enExample) | ||
| JP2011144190A (ja) | 抗癌剤の効果増強剤 | |
| EA037152B1 (ru) | Способ лечения рака | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2024527109A5 (enExample) | ||
| CN110198716A (zh) | 癌症治疗 | |
| JP2014512355A5 (enExample) | ||
| JP2022526159A5 (enExample) | ||
| JP2025516558A5 (enExample) | ||
| JP2023524789A5 (enExample) | ||
| TW201625243A (zh) | 用於治療黑素瘤之藥物組合 | |
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| JP2024518712A5 (enExample) | ||
| JP2023517671A5 (enExample) | ||
| CN121218987A (zh) | 雌激素受体降解剂和akt抑制剂的组合 | |
| IL299028A (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
| JP2024517788A5 (enExample) |